drugset / Trial / NCT02210104
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
Phase 1
Withdrawn
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn about the safety of giving CD4+T cells with ipilimumab and cyclophosphamide. CD4+T cells are a type of white blood cell. Researchers grow the T cells in the laboratory, and they are designed to find cancer cells and may kill them.
Timeline
- Start
- 2016-12
- Primary completion
- 2019-12
- Completion
- —
Outcome
Outcome not reported
Stopped: “Issues with tetramer staining”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD4+ T cells | Cell therapy | 1e+10 unknown | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |